Fighting drug-resistant bacteria with a new genre of antibodies

4625634104_3c5ce7d178_m
Anti-Cancer Antibodies (Photo credit: PNNL – Pacific Northwest National Laboratory)

Laboratory experiments showed that the colloid antibodies attached to and inactivated only their intended targets without harming other cells

In an advance toward coping with bacteria that shrug off existing antibiotics and sterilization methods, scientists are reporting development of a new family of selective antimicrobial agents that do not rely on traditional antibiotics. Their report on these synthetic colloid particles, which can be custom-designed to recognize the shape of specific kinds of bacteria and inactivate them, appears in the Journal of the American Chemical Society.

Vesselin Paunov and colleagues point out that many bacteria have developed resistance to existing antibiotics. They sought a new approach — one that bacteria would be unable to elude by mutating into drug-resistant forms. Their inspiration was the antibodies that the immune system produces when microbes invade the body. Those antibodies patrol the body for microbes and bind to their surfaces, triggering a chain of events in which the body’s immune system attacks and destroys the microbes.

Paunov’s team describes development and successful tests of synthetic colloid particles, called “colloid antibodies.” Colloids are materials in which tiny particles of one material are dispersed in another material. Milk is a colloid in which globules of fat are spread throughout water and other materials. The colloid antibody particles are shells packed with a killing agent. They are designed to recognize and bind to specific bacteria.

Laboratory experiments showed that the colloid antibodies attached to and inactivated only their intended targets without harming other cells. “We anticipate that similar shape selective colloid antibodies can potentially become a powerful weapon in the fight against antibiotic-resistant bacteria,” say the researchers. “They can also find applications as non-toxic antibacterial agents, preventing growth of harmful bacteria in various formulations.”

See Also
Princeton Engineering researchers led by A. James Link have discovered a compound that can kill a large of drug-resistant bacteria, making it a promising candidate for development as an antibiotic. Image courtesy the Centers for Disease Control and Prevention

 

The Latest Bing News on:
Drug resistant bacteria
The Latest Google Headlines on:
Drug resistant bacteria
[google_news title=”” keyword=”drug resistant bacteria” num_posts=”10″ blurb_length=”0″ show_thumb=”left”] [/vc_column_text]
The Latest Bing News on:
Colloid antibodies
  • The Antibody Initiative Antivenom
    on May 10, 2024 at 9:08 pm

    Antivenom (often spelled “antivenin”) is an antibody product that can disable a particular venom’s toxins. If injected quickly after a bite or sting, the antibodies in antivenom neutralize the venom, ...

  • Antibodies articles from across Nature Portfolio
    on April 29, 2024 at 5:00 pm

    Antibodies are secreted immunoglobulin molecules produced mainly by plasma cells. The antigen-binding site of the antibody has a unique structure that allows it to bind antigen in a highly ...

  • Gilead gives up on $4.9B antibody as solid tumor plan unravels
    on April 26, 2024 at 3:04 am

    After years of setbacks, the Big Biotech dealt a final blow to its anti-CD47 monoclonal antibody magrolimab Thursday by removing the remaining solid tumor trials from its pipeline. The program ...

  • Are Monoclonal Antibodies the Future of Long COVID Treatments?
    on April 22, 2024 at 4:59 pm

    Luckily, by late 2021, Pepe, of Dallas, Texas, had something to offer them: monoclonal antibodies. By that time, a variety of COVID antibody solutions had been developed by several pharmaceutical ...

  • Urinary Colloids in the Prevention of Kidney-Stone Formation
    on April 16, 2024 at 5:01 pm

    The reason for this is that the urine of a healthy person also contains colloids that prevent the precipitation of substances in such supersaturated solutions, as long as their degree of ...

  • EXCLUSIVE: Immunoprecise Antibodies and InterSystems Integrate Vector Search With LENSai For AI-Driven Healthcare Applications
    on March 28, 2024 at 5:00 am

    Immunoprecise Antibodies Ltd (NASDAQ:IPA), together with InterSystems, have collaborated to integrate the new vector search capability of the InterSystems IRIS data platform with Immunoprecise ...

  • This Company Is Using Generative AI To Design New Antibodies
    on January 10, 2023 at 4:59 am

    Absci Corporation (Nasdaq: ABSI) is using machine learning to transform the field of antibody therapeutics: Absci has put out a press release today announcing the ability to create new antibodies ...

  • Colloid & Interface Science Group
    on February 4, 2022 at 2:24 am

    The Colloid and Interface Science Group is one of the RSC's many Interest Groups. The Interest Groups are member driven groups which exist to benefit RSC members, and the wider chemical science ...

  • antibody drug
    on May 20, 2021 at 1:09 am

    The antibody drug developed by partners Sanofi and AstraZeneca is currently under regulatory review. ImCheck Therapeutics aims to broaden the reach of cancer immunotherapy with antibody drugs that ...

  • Nature knows best: fully human antibodies take the therapeutic lead
    on September 12, 2020 at 11:47 pm

    In little more than five years, German biotechnology company YUMAB (a phonetic play on HUMAB (human monoclonal antibody) in which the “Y” symbolizes the antibody structure) has become a global ...

The Latest Google Headlines on:
Colloid antibodies

[google_news title=”” keyword=”colloid antibodies” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]

What's Your Reaction?
Don't Like it!
0
I Like it!
0
Scroll To Top